Outcomes of patients with primary refractory and early relapsing large B-cell lymphoma are inferior in the CD19 CAR T era

Blood Immunology & Cellular Therapy · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles